Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MOK | Q9UQ07 | 3/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824471 | 0.87 | DHODH (0.53) | DHODHKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL4825985 | 0.86 | DHODH (0.52) | DHODHKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL16022196 | 0.74 | SLC18A3 (0.62) | DHODHKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL3738216 | 0.73 | DOT1L (0.57) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL31672140 | 0.73 | DOT1L (0.57) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL3822159 | 0.72 | SLC18A3 (0.67) | DHODHKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL15157030 | 0.71 | SLC18A3 (0.68) | DHODHKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL4259484 | 0.71 | MCHR1 (0.62) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL28844498 | 0.71 | TACR3 (0.75) | DHODHKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL31392690 | 0.69 | KDM4E (0.55) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348340-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-7189714-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2007-03-13 | — | — | US | disclosed |
| EP-1339706-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-6815447-B2 | 6-N-(2-AMINO-PYRIMIDIN-4-YL)QUINOLINE-6-AMINE DERIVATIVES; ANALGESICS | ASTRAZENECA AB (SE) | 2004-11-09 | — | — | US | disclosed |
| US-20040077644-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | disclosed |
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CHAUDHARI BIPINCHANDRA (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1339688-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036567-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077644-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | DHODH 3409/4885KDM4E 4744/4885KMT2A 4401/4885 |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | CACNA1B, CACNA1E, CACNA1G | DHODH 3089/4885KDM4E 4410/4885KMT2A 4155/4885 |
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | DHODH 3409/4885KDM4E 4744/4885KMT2A 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.